VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL
Status:
Active, not recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical trial
in 25,871 U.S. men and women investigating whether taking daily dietary supplements of
vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of
developing cancer, heart disease, and stroke in people who do not have a prior history of
these illnesses. This ancillary study is being conducted among participants in VITAL and will
examine whether vitamin D or fish oil: 1) reduces risk of clinical depressive syndrome, 2)
yields better mood scores over time, compared to placebo.
Phase:
N/A
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
National Institute of Mental Health (NIMH)
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins